FiercePharma1h
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
FierceBiotech4h
GSK-backed Ouro Medicines launches into T-cell engager space with $115M and a clinical-stage asset
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...
Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
The Biopharmaceutical Contract Manufacturing Market to Hit $38.07 Billion by 2029, Revenue to Double in the Next 6 Years – Arizton
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...
MM&M17h
Rx Rundown: Verdiva, Johnson & Johnson, Transcarent and more
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Dundalk Democrat19h
Wuxi employees make generous donation to St Vincent De Paul Dundalk
WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...